This $80 Presentation Templating Software is Like Hiring an Entire Digital Agency

Simplify pitch decks, presentations, and more.

Grow Your Business, Not Your Inbox

Stay informed and join our daily newsletter now!


2 min read

Disclosure: Our goal is to feature products and services that we think you’ll find interesting and useful. If you purchase them, Entrepreneur may get a small share of the revenue from the sale from our commerce partners.


In a remote working environment, you may not be able to meet teammates to fine-tune your pitches and presentations quite as much as you’d like. But you very likely have more time to send cold emails and make cold calls to present your product. Whether you’re a startup pitching investors or a consultant, a marketer creating ads, or a salesperson creating presentations and proposals, Kroma gives you a way to do it all more efficiently and with greater success.

Kroma is an intuitive pitching tool that’s as

Read More

New Maginito Website and Presentation

LONDON and VANCOUVER, British Columbia, Nov. 16, 2020 (GLOBE NEWSWIRE) — Mkango Resources Ltd. (AIM/TSX-V: MKA) (the “Company” or “Mkango”) is pleased to announce the launch of a new website for Maginito Limited (“Maginito”) (www.maginito.com), together with a new Maginito company presentation, available for download from the website via the following link: https://maginito.com/site/assets/files/1/20201103_maginito_presentation-1.pdf

Maginito is 75.5% owned by Mkango, which is completing a Feasibility Study for the Songwe Hill rare earths project in Malawi, and 24.5% owned by Talaxis Limited (“Talaxis”), which is focused on investment in and development of technology metal opportunities.

Maginito was established to pursue downstream green technology opportunities in the rare earths supply chain, encompassing neodymium (NdFeB) magnet recycling as well as innovative rare earth alloy, magnet and separation technologies.

Maginito’s strategy is underpinned by offtake rights for sustainably sourced primary and secondary raw materials, and geared to accelerating growth in the electric vehicle sector, wind

Read More

Poster presentation with ACD856 in Alzheimer’s now available on AlzeCure’s website

STOCKHOLM, Nov. 11, 2020 /PRNewswire/ — AlzeCure Pharma AB (publ) (FN STO: ALZCUR) (“AlzeCure”), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company’s poster presentation and abstract about the drug candate ACD856, which was presented at the annual Alzheimer’s conference CTAD, Clinical Trials in Alzheimer’s Disease, on November 4-7, 2020, are now available in full on the company’s website.

The poster presentation, given by AlzeCure’s CSO Johan Sandin, shows that ACD856 has the potential for widespread use in various types of cognitive memory disorders. The drug candidate strengthens the so-called neurotrophic signaling, biological systems that, among others, plays an important role in the function, communication as well as survival of the nerve cells. AlzeCure’s data show that ACD856 affects relevant neurotransmitters in the brain and the

Read More

Poster presentation with the Alzstatin platform now available on AlzeCure’s website

STOCKHOLM, Nov. 11, 2020 /PRNewswire/ — AlzeCure Pharma AB (publ) (FN STO: ALZCUR) (“AlzeCure”), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company’s poster presentation and abstract about the Alzstatin platform, which was presented at the annual Alzheimer’s conference CTAD, Clinical Trials in Alzheimer’s Disease, on November 4-7, 2020, are now available in full on the company’s website.

The poster presentation, given by Johan Sandin, CSO at AlzeCure, presents how the mechanisms in the research platform Alzstatin work and shows that the target mechanism within the platform is suitable as a new treatment for Alzheimer’s disease. Furthermore, data show that the class of drug substances being developed within AlzeCure’s platform, so-called gamma-secretory modulators, selectively affect the production of toxic Abeta-amyloid, without affecting the cleavage of

Read More